Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates

J Antimicrob Chemother. 2006 Jul;58(1):202-4. doi: 10.1093/jac/dkl152. Epub 2006 Apr 24.

Abstract

Objectives: The aim of this study was to assess the in vitro activity of the non-fluorinated quinolone PGE 9262932 against Streptococcus pneumoniae isolates with various resistance phenotypes: ciprofloxacin-resistant, macrolide-resistant, penicillin-resistant and trimethoprim/sulfamethoxazole-resistant.

Methods: The in vitro activity of PGE 9262932 against 2585 recent Canadian S. pneumoniae isolates with various resistance phenotypes was determined and compared with that of gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin. In particular, the activity of PGE 9262932 against ciprofloxacin-resistant isolates with defined parC and gyrA mutations was assessed.

Results: PGE 9262932 MIC90s were < or = 0.015 mg/L for all S. pneumoniae and 0.12 mg/L for the ciprofloxacin-resistant isolates. Resistance to penicillin, macrolides or trimethoprim/sulfamethoxazole had little effect on the PGE 9262932 MICs. The quinolone MIC50/90s were only slightly affected by the presence of one parC or gyrA mutation, but increased 2- to 16-fold in the presence of mutations in both parC and gyrA, depending on the specific quinolone. With each quinolone resistance genotype, the order of activity, based on MIC90, against the ciprofloxacin-resistant isolates was PGE 9262932, gemifloxacin, moxifloxacin, gatifloxacin and levofloxacin.

Conclusions: PGE 9262932 was the most active quinolone against all S. pneumoniae isolates, regardless of resistance phenotype.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Canada
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Bacterial*
  • Fluoroquinolones / pharmacology*
  • Genotype
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / microbiology
  • Quinolones / pharmacology*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • PGE 9262932
  • Quinolones
  • Ciprofloxacin